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BACKGROUND: DBC1/KIAA1967 (deleted in breast cancer 1) is a putative tumour-suppressor gene cloned from a heterozygously
deleted region in breast cancer specimens. Caspase-dependent processing of DBC1 promotes apoptosis, and depletion of
endogenous DBC1 negatively regulates p53-dependent apoptosis through its specific inhibition of SIRT1. Hereditary breast and
ovarian cancer susceptibility gene product BRCA1, by binding to the promoter region of SIRT1, is a positive regulator of SIRT1
expression.
METHODS: A physical interaction between DBC1 and BRCA1 was investigated both in vivo and in vitro. To determine the
pathophysiological significance of DBC1, its role as a transcriptional factor was studied.
RESULTS: We found a physical interaction between the amino terminus of DBC1 and the carboxyl terminus of BRCA1, also known as
the BRCT domain. Endogenous DBC1 and BRCA1 form a complex in the nucleus of intact cells, which is exported to the cytoplasm
during ultraviolet-induced apoptosis. We also showed that the expression of DBC1 represses the transcriptional activation function
of BRCT by a transient expression assay. The expression of DBC1 also inhibits the transactivation of the SIRT1 promoter mediated
by full-length BRCA1.
CONCLUSION: These results revealed that DBC1 may modulate the cellular functions of BRCA1 and have important implications in the
understanding of carcinogenesis in breast tissue.
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The gene encoding DBC1 (deleted in breast cancer 1) was
identified during a representative differential analysis to search
for candidate breast tumour-suppressor genes on a human
chromosome 8p21 region that is frequently deleted in breast
cancers (Hamaguchi et al, 2002). In this study, the expression of
DBC2 (deleted in breast cancer 2) was substantially decreased in
breast and lung cancer specimens. On the other hand, the
expression of DBC1 was not substantially abrogated in cancers
from any source. Molecular and cellular functions of DBC1 are
currently extensively investigated to reveal the physiological role of
DBC1 (Sundararajan et al, 2005; Kim et al, 2008; Zhao et al, 2008;
Cha et al, 2009). Endogenous DBC1 is a nuclear protein and is
thought to localise in the nucleus depending on its nuclear
localisation signal (NLS) at the amino terminus. During tumor
necrosis factor-a-induced apoptosis, DBC1 is translocated to the
cytoplasm with loss of the NLS by caspase-dependent cleavage and
this cleavage promotes apoptosis because of the death-promoting
activity of its carboxyl-terminal coiled-coil domain (Sundararajan
et al, 2005). Therefore, caspase-dependent cleavage of DBC1 may
function as a positive feedback mechanism to promote apoptosis
and this would explain how DBC1 functions as a tumour
suppressor. A recent study demonstrated that DBC1 promotes
p53-mediated apoptosis through specific inhibition of SIRT1, the
mammalian homologue of yeast silent information regulator 2
(Sir2) (Kim et al, 2008; Zhao et al, 2008). However, functions
of DBC1 in living cells still remain largely unknown and it should
be determined whether DBC1 has a pivotal role in tumour
suppression.
It is well known that the germ-line mutation of BRCA1
predisposes women to early-onset breast and ovarian cancer.
BRCA1 is predominantly located in the nucleus and is involved in
the basal transcriptional machinery (Scully et al, 1997; Anderson
et al, 1998). BRCA1 regulates stress-inducible gene expressions
such as p21 (Ouchi et al, 1998), p53 (Somasundaram et al, 1999),
and GADD45 (Jin et al, 2000). The carboxyl-terminal BRCA1,
referred to as the BRCT domain, has been shown to be involved in
double-stranded DNA repair and homologous recombination
(Callebaut and Mornon, 1997; Moynahan et al, 1999; Zhong
et al, 1999). BRCT is indispensable for normal cellular growth
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embryonic lethality (Hohenstein et al, 2001). The major function
of BRCT is thought to be a gene regulator, mediating BRCA1
function as a tumour suppressor. This hypothesis is based on
several lines of evidence, including that the autonomous trans-
activation function of BRCT was preserved in a recombinant
protein consisting of the BRCT domain fused to a GAL4 DNA
binding domain (Miyake et al, 2000). In addition, point mutations
in the BRCT domain derived from patients with inherited breast
cancer result in loss of transcriptional activity, and BRCA1 can also
function as a negative regulator on some gene promoters
(Chapman and Verma, 1996; Monteiro et al, 1996). This domain
has already been shown to be an interaction surface with a number
of transcription factors and co-regulators (Saka et al, 1997; Yarden
and Brody, 1999; Wada et al, 2004; Oishi et al, 2006). A recent
study revealed the interplay between SIRT1 and BRCA1 (Wang
et al, 2008). BRCA1 was shown to stimulate the expression level of
SIRT1 through binding to the specific promoter region of SIRT1,
and this interplay prompted us to search for the cross talk between
DBC1 and BRCA1.
To better understand the functional significance and the
transcriptional regulation of BRCA1, we investigated the physical
interaction between BRCA1 and DBC1. We found that DBC1
directly interacted with the BRCT domain. Our findings revealed
that the amino terminus of DBC1 binds directly to the BRCT
domain both in vitro and in vivo. We studied the effect of the
transcriptional regulation of BRCA1 driven by DBC1. These
findings establish a principal biological function of DBC1 in the
modulation of BRCA1 function, and further identify DBC1 as a
possible determinant and potential therapeutic target in breast
cancer.
MATERIALS AND METHODS
Cell culture
Human cervical adenocarcinoma HeLa (CCl-2), human breast
cancer MCF-7 (HTB-22), and human kidney 293T (CRL-11268) cell
lines were purchased from the American Type Culture Collection
(Manassas, VA, USA). These cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% foetal bovine
serum.
Plasmid construction
BRCA1 expression vectors, BRCT vectors, and reporter constructs
(17M8-AdMLP-luc) were described previously by Wada et al, 2004.
DBC1 (Clone ID 5496068) and SIRT1 (Clone ID 4518906)
expression vectors were purchased from Thermo Fisher Scientific
Open Biosystems (Huntsville, AL, USA). Fragments of DBC1
were inserted into pcDNA-Myc vector derived from pcDNA3
(Invitrogen, Carlsbad, CA, USA).
Chemicals and antibodies
Rabbit polyclonal antibodies were anti-DBC1 (produced in our
laboratory) and anti-acetyl-p53 (Upstate, Temecula, CA, USA,
catalogue no. 06-758). Mouse monoclonal antibodies were anti-
BRCA1 (Calbiochem, EMD Biosciences, Inc., LaJolla, CA, USA,
catalogue no. OP93T), anti-Myc (Invitrogen, catalogue no.
R95025), and anti-SIRT1 (Abnova, Taipei, Taiwan, catalogue no.
H00023411-M01). Anti-BRCA1 (catalogue no. sc-642), anti-p21
(catalogue no. sc-397), anti-p53 (catalogue no. sc-126), and
anti-actin (catalogue no. sc-47778) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Alexa
Fluor 488-conjugated donkey anti-mouse IgG (A-21202) and Alexa
Fluor 555-conjugated goat anti-rabbit IgG (A-21428) were
purchased from Invitrogen.
Immunoprecipitation and western blot
The formation of a DBC1–BRCA1 complex in HeLa and 293T cells
was analysed by immunoprecipitation. The whole-cell extracts of
HeLa cells were immunoprecipitated with anti-BRCA1 antibodies,
and subsequently immunoblotted by anti-DBC1 antibodies.
Reciprocal immunoprecipitation was also performed. Cells
(293T) transfected with indicated plasmids were lysed and
subjected to anti-FLAG M2 agarose (Sigma Aldrich, St Louis,
MO, USA). Immunoprecipitated materials were blotted with
anti-Myc antibodies to identify DBC1-containing complexes.
RNAi
The ablation of DBC1 and BRCA1 was performed by transfection
of HeLa cells with small interfering RNA (siRNA) duplex oligos
synthesised by Qiagen (Hilden, Germany). Control siRNA (AllStars
Negative Control siRNA, Qiagen, 1027281), DBC1-specific siRNA
(DBC1-RNAi: 50-AAACGGAGCCUACUGAACA-30, which covered
mRNA regions of nucleotides 1379–1397 (amino acids 460–466)
of DBC1, and KIAA1967-RNAi, SI00461853), and BRCA1-specific
siRNA (#14 (SI02664361) and #15 (SI02664368)) were transfected
using HyperFect reagent (Qiagen).
GST pull-down assay
Glutathione S-transferase (GST) fusion proteins or GST alone were
expressed in Escherichia coli and immobilised on glutathione–
sepharose 4B beads (GE Healthcare UK Ltd., Buckinghamshire,
UK). GST proteins were incubated with [
35S] methionine-labelled
proteins using a TNT-coupled transcription–translation system
(Promega Co., Madison, WI, USA). Unbound proteins were
removed and specifically bound proteins were eluted and analysed
by SDS polyacrylamide gel electrophoresis.
Luciferase assay and mammalian two-hybrid assay
Transfection was performed with Effectene reagent (Qiagen)
according to the manufacturer’s recommendation. For luciferase
assay, indicated expression vectors and GAL4 vectors were co-
transfected with 17M8-AdMLP-luc or SIRT1-luc. For mammalian
two-hybrid assay, GAL4 vectors and VP16 vectors were co-
transfected. As an internal control to equalise transfection efficiency,
phRL CMV-Renilla vector (Promega Co.) was also transfected in all
experiments. Individual transfections, each consisting of triplicate
wells, were repeated at least three times (Wada et al, 2004).
Fluorescence microscopy
Cells (MCF-7) were grown on 12mm BD BioCoat glass coverslips
(BD Biosciences, NJ, USA, 354085) in six-well plates before
induction of apoptosis. The cells were treated or not treated with
irradiation of ultraviolet (UV) light (0.24J), fixed with phosphate-
buffered saline (PBS) containing 4% paraformaldehyde, and
permeabilised in PBS with 0.2% (v/v) Triton X-100. After blocking,
the cells were incubated sequentially with anti-BRCA1 and anti-
DBC1 antibodies. Secondary antibodies were Alexa Fluor 488-
conjugated donkey anti-mouse IgG and Alexa Fluor 555-
conjugated goat anti-rabbit IgG. The slides were briefly counter-
stained and analysed under a confocal fluorescence microscope
(Carl-Zeiss MicroImaging Inc., Oberkochen, Germany). Colocali-
sation was quantified using LSM7 series-ZEN200x software
(Carl-Zeiss MicroImaging Inc.), and the ratio of colocalisation
pixels vs total pixels in the target area was determined. The degree
of colocalisation signal is expressed as mean±standard deviation.
Repression of BRCA1 by DBC1
H Hiraike et al
1062
British Journal of Cancer (2010) 102(6), 1061–1067 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sImmunohistochemistry
The procedure for immunohistochemical study has been described
by Wada-Hiraike et al, 2006. The primary antibody used was
anti-DBC1, and the ChemMate EnVision Detection system (DAKO,
Carpinteria, CA, USA) was used to visualise the signal.
Chromatin immunoprecipitation assay
Soluble HeLa chromatin for PCR amplification was essentially
prepared as described by Oishi et al, 2006. Subconfluent HeLa cells
were crosslinked with 1.5% formaldehyde at room temperature for
15min, and washed twice with ice-cold PBS. The cell pellet was
then resuspended in 0.2ml lysis buffer and sonicated by Bioruptor
UCD-250 (Cosmo Bio, Co., Ltd., Tokyo, Japan). The sheared
soluble chromatin was then subjected to immunoprecipitation
with specific antibodies and protein G-sepharose with salmon
sperm DNA (Upstate). After an extensive wash, the beads were
eluted. The eluate was incubated for 6h at 651C to reverse the
formaldehyde crosslink. The extracted DNA was purified using the
QIAquick PCR purification kit (Qiagen). PCR was performed using
specific primers (Wang et al, 2008).
RESULTS
DBC1 and BRCA1 interact in vivo and in vitro
To determine the interaction between endogenous DBC1 and
BRCA1 in cultured human cells, cell extracts from HeLa cells were
immunoprecipitated with anti-BRCA1 antibodies or with preim-
mune IgG. The immunoblotting analysis using anti-DBC1 anti-
bodies revealed the existence of DBC1 in cell lysate immuno-
precipitates (Figure 1A), which indicates that DBC1 physically
associates with BRCA1 in living cells. Reciprocal immunoprecipi-
tation analysis confirmed this association (Figure 1A). In addition,
Flag-tagged BRCA1 and Myc-tagged DBC1 were each transfected in
293T cells and extracts of transfected cells were immunoprecipi-
tated with anti-FLAG M2 agarose beads. Western blotting analysis
with anti-Myc antibodies revealed the existence of Myc-tagged
DBC1 in the protein extract of immunoprecipitates (Figure 1B),
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Figure 1 In vivo and in vitro association between DBC1 and BRCA1, and mapping of the BRCT-interacting region of DBC1. (A) The formation of a
DBC1–BRCA1 complex in HeLa cells was analysed by co-immunoprecipitation (IP) with antibodies to BRCA1 or preimmune IgG, followed by
immunoblotting (IB) using anti-DBC1 antibodies. The immunoprecipitates were subjected to 30ml of protein G sepharose 4 Fast Flow and bound proteins
were detected by western blotting. Reciprocal co-immunoprecipitation with antibodies to DBC1 and subsequent IB confirmed the complex formation of
DBC1 and BRCA1. (B) The formation of a DBC1–BRCA1 complex in 293T cells was analysed by IP with anti-Flag M2 agarose beads, followed by IB using
anti-Myc antibodies. Bound proteins were detected by western blotting. (C) Mapping of the BRCT-interacting region of DBC1 using glutathione
S-transferase (GST)–BRCT and DBC1. Bacterially expressed GST fusion proteins immobilised on beads were used in in vitro pull-down assays. Full-length
DBC1 was in vitro translated in the presence of [
35S] methionine using a TNT-coupled in vitro translation system. Labelled DBC1 was then incubated with
GST–BRCT. The mixtures were washed and subjected to SDS polyacrylamide gel electrophoresis (PAGE) and analysed. Polyacrylamide gels were stained
briefly with Coomassie Brilliant Blue to verify the loading amounts of fusion proteins. (D) A schematic diagram of the structure of DBC1 is shown. Fragments
of DBC1 ((amino acids 1–230), (230–500), (500–750), and (750–923)) were in vitro translated using a TNT-coupled in vitro translation system. Labelled
DBC1 was incubated with GST–BRCT. The mixtures were extensively washed and subjected to SDS–PAGE and then analysed by autoradiography.
(E) Mammalian two-hybrid interaction analysis. Cells (293T) were transfected with the indicated combinations of mammalian expression vectors encoding
GAL4, GAL4–BRCT, the herpes simplex virus VP16 transactivation domain (VP16), and VP16-DBC1 chimera. At 24h after transfection, cells were
harvested, and transfected whole-cell lysates were assayed for luciferase activity produced from a co-transfected GAL4 DNA binding site-driven reporter
template (17M8-AdMLP-luc). GAL–BRCT shows additive transactivation when co-transfected with VP-DBC1 N, suggesting the interaction between BRCT
and DBC1 (1–230) in vivo.
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address the functional importance of the DBC1–BRCA1 interac-
tion, in vitro-translated DBC1 in the presence of [
35S] methionine
was incubated with GST and GST fusion BRCT. As clearly shown in
Figure 1C, [
35S]-labelled DBC1 bound the GST-fused BRCT
protein, consistent with the results from the immunoprecipitation
assay. These data indicated that DBC1 directly interacted with the
BRCT domain. To map the region of DBC1 that interacts with
the BRCT domain, GST pull-down assays were performed to test
for the interaction with GST–BRCT and fragments of in vitro-
translated DBC1 (Figure 1D). The amino-terminal region of DBC1
including the NLS interacted with the BRCT domain. These
findings indicate that the DBC1 amino terminus including the NLS
and the BRCT domain are both necessary and sufficient for the
interaction between DBC1 and BRCA1. We further confirmed the
binding of the BRCT domain to the DBC1 amino terminus using
mammalian two-hybrid assays. In this assay, the VP16-fused
amino terminus of DBC1 containing the NLS (VP-DBC1 N)
exhibited a prominent interaction with the BRCT domain, whereas
DBC1 lacking the amino terminus (VP-DBC1 DN) showed no
interaction, underscoring the results of immunoprecipitation and
GST pull-down experiments (Figure 1E).
DBC1 and BRCA1 colocalise in intact and apoptotic cells
Immunohistochemical studies using human breast specimens
showed nuclear staining of DBC1 in the duct and adipose tissue
(Figures 2A and B, respectively). Most breast cancer cells exhibited
nuclear staining (Figure 2C), but this nuclear staining of DBC1 was
not observed in cancer cells with an enlarged nucleus (Figure 2D,
arrows). As previously shown, during tumor necrosis factor-a-
induced apoptosis, DBC1 is translocated to the cytoplasm with a
loss of the amino terminus containing the NLS (Sundararajan et al,
2005), and the expression of BRCA1 is downregulated by caspase-
3-mediated cleavage during UV-induced apoptosis (Zhan et al,
2002). The changes in cellular distribution of DBC1 and BRCA1
during apoptotic processes were examined comprehensively under
a confocal microscope in MCF-7 cells treated by UV-mediated
death signalling. Both DBC1 (Alexa Fluor 555-conjugated anti-
rabbit IgG, red) and BRCA1 (Alexa Fluor 488-conjugated
anti-mouse IgG, green) were abundantly expressed and colocalised
in the nuclei of control cells (Figure 2E, 1–4). In contrast to
healthy cells, both DBC1 and BRCA1 are translocated to the
cytoplasm in cells showing apoptotic morphological changes
(Figure 2E, 5–8). The degree of colocalisation signal was
quantified in both control and apoptotic cells, and these data
indicated that UV-mediated apoptosis signalling prompted the
translocation of these proteins (Figure 2F).
DBC1 represses the transcriptional activation function of
BRCT
The result that the BRCT domain interacts with DBC1 led us
to examine the role of DBC1 in the transactivation function of
GAL4-fused BRCT. Transient transfection assays were performed
using a 17M8-AdMLP-luc luciferase reporter plasmid, carrying
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Figure 2 Immunohistochemical detection of DBC1 in human breast tissues and colocalisation of BRCA1 and DBC1 in MCF-7 human breast cancer cells.
(A–D) Breast specimens were obtained at the time of diagnosis of breast cancer in accordance with the guidelines of the Ethical Board of Komagome
Hospital. DBC1 showed nuclear staining of ductal epithelium (A) and adipose tissue (B) in breast specimens. DBC1 expression was observed in the nuclei of
cancer tissues (C). Cancer cells exhibiting an enlarged nucleus showed a complete loss of DBC1 expression (D, arrow). (E) MCF-7 cells were either treated
or not treated by ultraviolet (UV) light (0.24J), fixed, and permeabilised. Cells were incubated with primary antibodies and subsequently with secondary
antibodies. The expression of DBC1 (red) and BRCA1 (green) was investigated under confocal fluorescence microscopy (Carl-Zeiss). Representative
immunofluorescence studies are shown (E, 1–4; control, 5–8; UV exposure for 10min, E3 and E7; merge, E4 and E8; 40,6-diamino-2-phenylindole staining).
Arrows in E5–8 indicate a cell showing apoptotic morphological changes with the cytoplasmic expression of DBC1 and BRCA1. Bars indicate 10mm.
(F) The degree of colocalisation (BRCA1 and DBC1) was measured using a confocal microscope. The colocalisation signal was quantified in the nucleus and
cytoplasm of cells separately.
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of the major late promoter of adenovirus (AdMLP) driving the
expression of the firefly luciferase gene. Although the GAL4–BRCT
fusion protein (GAL–BRCT) activated the promoter activity of the
reporter plasmid in 293T cells, the transcriptional activity of BRCT
was significantly decreased by the expression of DBC1 in luciferase
assays (Figure 3). DBC1 lacking an interaction domain with
BRCA1 (DBC1 DN) lost its ability to inhibit the BRCT-mediated
transactivation function (Figure 3). DBC1 lacking a binding region
with SIRT1 deacetylase (DBC1 DLZ) suppressed the GAL–BRCT
transactivation function. SIRT1 showed no influence on the
GAL–BRCT transactivation function and on the repression of
GAL–BRCT by DBC1. The BRCT-repression function of DBC1 was
unaffected in the presence of resveratrol, a major activator of
SIRT1, and trichostatin A, a histone deacetylase inhibitor (data not
shown). These results suggest that the amino terminus of DBC1
has a significant role in the repression of GAL–BRCT and SIRT1
has no role in regulating the GAL–BRCT function.
DBC1 disrupts BRCA1-mediated SIRT1 expression
The previous chromatin immunoprecipitation assay showed that
BRCA1 interacted with the SIRT1 promoter region between 1354
and 1902 and this binding resulted in an elevated expression of
SIRT1 (Wang et al, 2008). We investigated whether DBC1 has an
effect on the BRCA1-mediated stimulation of the SIRT1 promoter.
An analysis of the effect of DBC1 on SIRT1-luciferase constructs
containing various lengths of SIRT1 promoter regions upstream of
the luciferase gene was performed and DBC1 demonstrated a
specific downregulation of BRCA1-mediated stimulation on the
SIRT1 promoter (SIRT1 1-2852 Luc), evidenced by the expression
of DBC1 (Figure 4A). As expected, DBC1 DN showed no influence
to inhibit the BRCA1-mediated transactivation function of SIRT1-
luciferase reporter constructs, whereas DBC1 DLZ showed repres-
sion on the SIRT1-luciferase transactivation function mediated by
BRCA1. We next examined the effect of siRNA-mediated depletion
of DBC1 or BRCA1 on their downstream genes. As expected,
knockdown of BRCA1 expression by BRCA1-specific siRNA
completely abrogated the expression of SIRT1 (Figure 4B, lanes 4
and 5), validating the previous report that the expression of SIRT1
is indeed dependent on BRCA1 (Wang et al, 2008). As shown in
Figure 4B, lanes 2 and 3, depletion of endogenous DBC1 increased
the expression of SIRT1. To demonstrate that SIRT1 functions on
the p53 acetylation level (Zhao et al, 2008), we tested whether
depletion of BRCA1 or DBC1 indeed influences the expression of
acetylated p53. Consistent with previous studies (Kim et al, 2008;
Zhao et al, 2008), RNAi-mediated knockdown of DBC1 expression
resulted in hypoacetylation of p53 (Figure 4B, lanes 2 and 3),
whereas depletion of endogenous BRCA1 had no influence on the
expression level of acetylated p53 (Figure 4B, lanes 4 and 5).
Depletion of DBC1 resulted in a downregulation of p21, a
transcriptional target of BRCA1 (Figure 4B, lanes 2 and 3). Thus,
our data demonstrate that DBC1 has a critical role in regulating
downstream gene expressions dependent on BRCA1 in vivo such
as SIRT1 and p21. To test whether DBC1 and BRCA1 were indeed
recruited to the SIRT1 promoter, we performed a chromatin
immunoprecipitation assay using the SIRT1 gene promoter
1354–1902, a region known to recruit BRCA1 (Wang et al,
2008). As expected, a clear recruitment of endogenous BRCA1 to
the target sequence (1354–1902) in the SIRT1 promoter was
observed in HeLa cells (Figure 4C). Besides this BRCA1 recruit-
ment, DBC1 and SIRT1 were also detected in the promoter region,
presumably reflecting the complex formation of BRCA1-DBC1 on
the SIRT1 promoter (Figure 4C).
DISCUSSION
The transcriptional activation function of BRCT is believed to be a
key to its tumour-suppressor activity (Chapman and Verma, 1996;
Monteiro et al, 1996). The importance of BRCT for transcriptional
control and growth suppression is also highlighted by the fact that
cancer-associated mutations attenuated both, but a neutral
polymorphism did not (Humphrey et al, 1997; Yarden and Brody,
1999). BRCT possesses an autonomous folding unit defined by
conserved clusters of hydrophobic amino acids, and BRCT is likely
to represent a protein interaction surface (Saka et al, 1997).
Although a number of proteins have been identified to interact
with the BRCT domain, most of them activate the transcriptional
function of BRCT (Wada et al, 2004; Oishi et al, 2006), and
the repressors of BRCT have been poorly studied until now
(Chen et al, 2001). Here, we clearly showed that endogenous DBC1
associated with BRCA1 in vivo and in vitro, which suggests the
possibility that DBC1 might have a functional relationship with
BRCA1-related phenotypical changes. This interaction between
BRCA1 and DBC1 was physiologically functional because our
results indicated that the DBC1-containing complex might
modulate a role of BRCA1 in living cells, repressing BRCT
function. In this respect, DBC1 seems to have a tumourigenic role
in living cells. The BRCT domain is found in a diverse group of
proteins implicated in DNA repair and cell-cycle checkpoint
control (Bork et al, 1997; Callebaut and Mornon, 1997). A point
mutation within the BRCT domain (A1708E) was shown to be
critical for DNA damage response by treatment with DNA-
damaging agent methylmethane sulphonate (Zhong et al, 1999).
Thus, repression of BRCT has implications both in tumourigenic
and in defective DNA repair processes. Our results also indicated
that DBC1 suppressed BRCA1-dependent transcriptional regula-
tion, because SIRT1-luciferase activity was attenuated by the
expression of DBC1. Together with the result of chromatin
immunoprecipitation assay, these data suggest the possibility that
DBC1 might be involved in the basal transcriptional machinery
because BRCA1 associates with RNA polymerase II holoenzyme
(Scully et al, 1997; Anderson et al, 1998). DBC1 would serve as a
transcriptional repressive factor to manipulate transcriptions,
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Figure 3 DBC1 represses transcription of GAL4–BRCT through its
amino-terminal domain. Transient transfection assays were performed to
examine the co-factor activity of DBC1 in the transactivation function of
GAL4-fused BRCT. Cells (293T) were transfected with the indicated
combinations of mammalian expression plasmids. At 24h after transfection,
the cells were harvested, and transfected whole-cell lysates were assayed
for luciferase activity produced from the reporter plasmid (17M8-AdMLP-
luc). DBC1 showed a specific repression of the transactivation function of
BRCT. The amino terminus of DBC1 was indispensable for this inhibition of
BRCT. SIRT1, a binding partner that has roles in cell senescence and
tumourigenicity, had no effect on the transactivation function of BRCT.
phRL Renilla CMV-luc vector was transfected as a control of transfection
efficiency. Each experiment was repeated at least three times in triplicate.
Error bars represent s.d.
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p21. Consistent with these results, our recent data have also shown
that DBC1 suppresses the ligand-dependent transcriptional
activation function of ERb (Koyama et al, 2010).
Apoptosis is a normal physiological process that has an
important role in embryonic development and in tissue homoeo-
stasis maintenance. As apoptosis is genetically programmed, its
dysfunction contributes to tumour promotion. The previous study
showed that BRCA1 is cleaved at amino acid 1151–1154 (DLLD)
by caspase-3 during UV-C-induced apoptosis, and the cleaved
fragment of BRCA1, containing the BRCT domain, induced cell
death through activation of BRCA1 downstream effectors,
GADD45 and JNK (Jin et al, 2000). Another study reported that
DBC1 is translocated from the nucleus to the mitochondria during
apoptosis (Sundararajan et al, 2005). Thus, our results of
immunofluoresence showing that the cleavage of DBC1 and
BRCA1 after death signalling promotes their cytoplasmic shuttling
indicated that BRCA1 and DBC1 may function synergistically in
the apoptotic pathway. It seems reasonable to hypothesise that the
cells devoid of nuclear DBC1 staining may be apoptotic. Loss of
nuclear DBC1 staining in tissues would be speculated as a marker
of therapy efficiency.
The accumulation of DNA damage activates p53 and induces
cell-cycle arrest and apoptosis. Acetylation of p53 has been shown
to augment p53 DNA binding and to regulate the stability of p53 by
inhibiting its ubiquitination by MDM2. In response to DNA
damage, acetylation of p53 is stimulated and acetylated p53
enhances its ability to induce cell-cycle arrest, apoptosis, and DNA
damage repair (Smith and La Thangue, 2005). Consistent with the
previous report by Zhao et al, 2008, inactivation of endogenous
DBC1 leads to hypoacetylation of p53. This would suggest that
abrogation of DBC1 causes malfunctions of p53, including
defective DNA repair activities. Furthermore, as we discussed
above, repression of the BRCT transactivation function may have
significance in impaired DNA damage response. The mechanism
by which DBC1 regulates DNA damage machinery seems to be
complicated, as DBC1 may possess dual roles in promoting and
inhibiting DNA repair, because depletion of DBC1 also results in
an increased expression of SIRT1, which possesses DNA repair
activity (Jeong et al, 2007). We have to further confirm the effect of
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results provide new insight into the fact that DBC1 may serve, at
least in part, as a DNA damage response machinery.
In conclusion, our data indicate that DBC1 has an important
role in regulating BRCA1-mediated functions through binding to
the BRCT domain. In addition to its inhibition of the deacetylase
activity of SIRT1, DBC1 represses the expression of SIRT1 by
associating with BRCA1. DBC1 may be involved both in
tumourigenic and anti-tumourigenic processes. This conflicting
mechanism can be the reason why expression of DBC1 was not
substantially abrogated in various cancers from any type of tissue
(Hamaguchi et al, 2002). Therefore, both inhibitors and activators
of DBC1 would be therapeutically beneficial, by affecting different
DBC1-mediated regulatory pathways together with BRCA1. These
results suggest that the failure of binding between BRCA1 and
DBC1 may be a key event in cancer predisposition.
ACKNOWLEDGEMENTS
This study was supported by a Grant-in-Aid for Scientific Research
from the Ministry of Education, Science and Culture, JMS Bayer
Schering Pharma Grant, and Kowa Life Science Foundation, Japan.
We thank Dr Rui-Hong Wang and Chu-Xia Deng for SIRT1-
luciferase vectors, and Dr Ja-Eun Kim for DBC1 DLZ construct.
REFERENCES
Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD (1998)
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex
via RNA helicase A. Nat Genet 19: 254–256
Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV (1997)
A superfamily of conserved domains in DNA damage-responsive cell
cycle checkpoint proteins. FASEB J 11: 68–76
Callebaut I, Mornon JP (1997) From BRCA1 to RAP1: a widespread BRCT
module closely associated with DNA repair. FEBS Lett 400: 25–30
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ,
Kang MJ, Lee DG, Moon WS, Jang KY (2009) Expression of DBC1 and
SIRT1 is associated with poor prognosis of gastric carcinoma. Clin
Cancer Res 15: 4453–4459
Chapman MS, Verma IM (1996) Transcriptional activation by BRCA1.
Nature 382: 678–679
Chen GC, Guan LS, Yu JH, Li GC, Choi Kim HR, Wang ZY (2001)
Rb-associated protein 46 (RbAp46) inhibits transcriptional transactiva-
tion mediated by BRCA1. Biochem Biophys Res Commun 284: 507–514
Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L,
Walsh T, Welcsh P, King MC, Wigler MH (2002) DBC2, a candidate for a
tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA
99: 13647–13652
Hohenstein P, Kielman MF, Breukel C, Bennett LM, Wiseman R,
Krimpenfort P, Cornelisse C, van Ommen GJ, Devilee P, Fodde R
(2001) A targeted mouse Brca1 mutation removing the last BRCT repeat
results in apoptosis and embryonic lethality at the headfold stage.
Oncogene 20: 2544–2550
Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD
(1997) Human BRCA1 inhibits growth in yeast: potential use in
diagnostic testing. Proc Natl Acad Sci USA 94: 5820–5825
Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH,
Lee KH (2007) SIRT1 promotes DNA repair activity and deacetylation of
Ku70. Exp Mol Med 39: 8–13
Jin S, Zhao H, Fan F, Blanck P, Fan W, Colchagie AB, Fornace Jr AJ,
Zhan Q (2000) BRCA1 activation of the GADD45 promoter. Oncogene 19:
4050–4057
Kim JE, Chen J, Lou Z (2008) DBC1 is a negative regulator of SIRT1. Nature
451: 583–586
Koyama S, Wada-Hiraike O, Nakagawa S, Tanikawa M, Hiraike H,
Miyamoto Y, Sone K, Oda K, Fukuhara H, Nakagawa K, Kato S,
Yano T, Taketani Y (2010) Repression of estrogen receptor b function by
putative tumor suppressor DBC1. Biochem Biophys Res Commun; e-pub
ahead of print 13 January 2010. doi: 10.1016/j.bbrc. 2010. 01. 025
Miyake T, Hu YF, Yu DS, Li R (2000) A functional comparison of BRCA1
C-terminal domains in transcription activation and chromatin
remodeling. J Biol Chem 275: 40169–40173
Monteiro AN, August A, Hanafusa H (1996) Evidence for a transcriptional
activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA
93: 13595–13599
Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls
homology-directed DNA repair. Mol Cell 4: 511–518
Oishi H, Kitagawa H, Wada O, Takezawa S, Tora L, Kouzu-Fujita M,
Takada I, Yano T, Yanagisawa J, Kato S (2006) An hGCN5/TRRAP
histone acetyltransferase complex co-activates BRCA1 transactivation
function through histone modification. J Biol Chem 281: 20–26
Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H (1998) BRCA1
regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:
2302–2306
Saka Y, Esashi F, Matsusaka T, Mochida S, Yanagida M (1997) Damage and
replication checkpoint control in fission yeast is ensured by interactions
of Crb2, a protein with BRCT motif, with Cut5 and Chk1. Genes Dev 11:
3387–3400
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM,
Parvin JD (1997) BRCA1 is a component of the RNA polymerase II
holoenzyme. Proc Natl Acad Sci USA 94: 5605–5610
Smith L, La Thangue NB (2005) Signalling DNA damage by regulating p53
co-factor activity. Cell Cycle 4: 30–32
Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH,
Weber BL, el-Deiry WS (1999) BRCA1 signals ARF-dependent stabiliza-
tion and coactivation of p53. Oncogene 18: 6605–6614
Sundararajan R, Chen G, Mukherjee C, White E (2005) Caspase-dependent
processing activates the proapoptotic activity of deleted in breast
cancer-1 during tumor necrosis factor-alpha-mediated death signaling.
Oncogene 24: 4908–4920
Wada-Hiraike O, Hiraike H, Okinaga H, Imamov O, Barros RP,
Morani A, Omoto Y, Warner M, Gustafsson JA (2006) Role of estrogen
receptor beta in uterine stroma and epithelium: Insights from
estrogen receptor beta /  mice. Proc Natl Acad Sci USA 103:
18350–18355
Wada O, Oishi H, Takada I, Yanagisawa J, Yano T, Kato S (2004) BRCA1
function mediates a TRAP/DRIP complex through direct interaction with
TRAP220. Oncogene 23: 6000–6005
Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C,
Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T,
Deng CX (2008) Interplay among BRCA1, SIRT1, and survivin during
BRCA1-associated tumorigenesis. Mol Cell 32: 11–20
Yarden RI, Brody LC (1999) BRCA1 interacts with components
of the histone deacetylase complex. Proc Natl Acad Sci USA 96:
4983–4988
Zhan Q, Jin S, Ng B, Plisket J, Shangary S, Rathi A, Brown KD, Baskaran R
(2002) Caspase-3 mediated cleavage of BRCA1 during UV-induced
apoptosis. Oncogene 21: 5335–5345
Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W (2008) Negative regulation
of the deacetylase SIRT1 by DBC1. Nature 451: 587–590
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD,
Lee WH (1999) Association of BRCA1 with the hRad50-hMre11-p95
complex and the DNA damage response. Science 285: 747–750
Repression of BRCA1 by DBC1
H Hiraike et al
1067
British Journal of Cancer (2010) 102(6), 1061–1067 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s